Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma

BACKGROUND: Pazopanib is indicated in the first-line treatment of metastatic renal cell cancer (mRCC). The aim of this study was to review the efficacy, safety, and pharmacokinetics of pazopanib and see how these aspects are linked to clinical practice. METHODS: A non-exhaustive systematic review wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Méndez-Vidal, María José, Molina, Áurea, Anido, Urbano, Chirivella, Isabel, Etxaniz, Olatz, Fernández-Parra, Eva, Guix, Marta, Hernández, Carolina, Lambea, Julio, Montesa, Álvaro, Pinto, Álvaro, Ros, Silverio, Gallardo, Enrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258404/
https://www.ncbi.nlm.nih.gov/pubmed/30477570
http://dx.doi.org/10.1186/s40360-018-0264-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258404/
https://www.ncbi.nlm.nih.gov/pubmed/30477570
http://dx.doi.org/10.1186/s40360-018-0264-8

Ejemplares similares